But the issue with CRISPR is that it's been a slow rollout, and its business continues to incur significant losses. Is it ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a ...

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

Intellia is now able to continue both Phase III trials of nex-z. Credit: Piotr Swat / Shutterstock.com (Piotr Swat / ...

Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...